Clinical, Metabolic and Endocrine Parameters in Response to Metformin in Obese Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind and Placebo-Controlled Trial

Abstract

There is still some controversy concerning the effects of metformin in the treatment of Polycystic Ovary Syndrome (PCOS). The aim of this study was to asses the effect of metformin on clinical, metabolic and hormone parameters in obese women with PCOS. Thirty obese, non-diabetic women with PCOS received 500 mg of metformin or placebo, TID, over 90 days. Assessed parameters included body mass index, waist-to-hip ratio, blood pressure, FSH, LH, total testosterone, SHBG, fasting insulinemia, insulin-to-glucose ratio, total, HDL and LDL cholesterol, triglycerides, and menstrual cycles before and after the use of the drugs. Before treatment, patients did not differ in the two groups. After 90 days of metformin use, PCOS women presented significantly lower levels of total testosterone (p = 0.030) and total cholesterol (p = 0.023) compared to the women that used placebo. The other parameters did not differ between the groups. In conclusion, obese women with PCOS may benefit from the use of metformin through the reduction of hyperandrogenemia, total cholesterol, and possibly by restoration of regular menstrual cycles. Further studies with longer follow-ups are necessary to determine cardiovascular and endometrial metformin benefits and insulin-resistance decrease in women with polycystic ovary syndrome.

Obesity - Hyperandrogenism - Insulin Resistance - Anovulation - Hyperinsulinemia - Cholesterol - Insulin-Sensitizing Drugs

References

• 1 Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.  J Clin Endocrinol Metab. 1998;  83 3078-3082
• 2 Zawadski J K, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Evans JR, Hersaltine S, Marriam GR (eds). Polycystic Ovary Syndrome Boston; Blackwell 377-384 1990
• 3 Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome.  Diabetes. 1989;  38 1165-74
• 4 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.  J Clin Endocrinol Metab. 1999;  84 165-169
• 5 Talbott E, Clerici A, Berga S L, Kuller L, Guzick D, Detre K, Daniels T, Engberg R A. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study.  J Clin Epidemiol. 1998;  51 415-422
• 6 Wild R A, Alaupovic P, Parker I J. Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance.  Am J obstet Gynecol. 1992;  166 1191-1197
• 7 Guzick D S, Talbott E, Sutton-Tyrell K, Herzog H C, Kuller L H, Wolfson J r. Carotid atherosclerosis in women with polycystic ovary syndrome; initial results from a case-control study.  Am J Obstet Gynecol. 1996;  174 1224-1232
• 8 Rajkhowa M, Neary R H, Kumpatla P, Game F L, Jones P W, Obhrai M S, Clayton R N. Altered composition of high density lipoproteins in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 1997;  82 3389-3394
• 9 Velazquez E M, Mendoza S, Hamer T, Sosa F, Glueck C J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.  Metabolism. 1994;  43 647-654
• 10 Nestler J E, Jakubowicz D J. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.  N Eng J Med. 1996;  335 617-623
• 11 Ünlühizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.  Clin Endocrinol. 1999;  51 231-236
• 12 Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.  J Clin Endocrinol Metab. 2000;  85 139-146
• 13 Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni G E, Filicori M, Morselli-Labate A M. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.  J Clin Endocrinol Metab. 2000;  85 2767-2774
• 14 Crave J C, Fimbel S, Lejeune H, Cugnardey N, Déchaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.  J Clin Endocrinol Metab. 1995;  80 2057-2062
• 15 Açbay Ö, Gündogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome?.  Fertil Steril. 1996;  65 946-949
• 16 Ehrmann D A, Cavaghan M K, Imperial J, Sturis J, Rosenfield R L, Polonsky K S. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 1997;  82 524-530
• 17 Ferriman D, Gallwey J D. Clinical assessment of body hair growth in women.  J Clin Endocrinol Metab. 1961;  21 1440-1447
• 18 World Health Organization .Diet, nutrition and prevention of chronic disease. Report of a WHO Study Group. Technical Report Series 797. Geneva; WHO 203 1990
• 19 World health Organization Study Group .Prevention of Diabetes Mellitus. Geneva; World Health Organization, WHO Technical Report Series 844 100 1994
• 20 Spritzer P M, Billaud L, Thalabard J, Kuttenn F, Mauvais-Jarvis P. Cyproterone acetate versus hydrocortisone treatment in late onset adrenal hyperplasia.  J Clin Endocrinol Metab. 1990;  70 642-645
• 21 Harris M I, Hadden W C, Knowler W. International criteria for the diagnosis of diabetes and impaired glucose tolerance.  Diabetes Care. 1985;  8 562-567
• 22 Spritzer P M, Poy M, Wiltgen D, Mylius L S, Capp E. Leptin concentrations in hirsute women with polycystic ovary sydrome or idiopathic hirsutism: influence on LH and relationship with hormonal, metabolic and anthropometric measurements.  Hum Reprod. 2001;  16 1340-1346
• 23 de Fronzo R A, Tobin J D, Adres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance.  Am J Physiol. 1979;  237 E214-E223
• 24 Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.  Eur J Endocrinol. 1998;  138 269-274
• 25 Pirwany L R, Yates R WS, Cameron I T, Fleming R. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.  Hum Reprod. 1999;  14 2963-2968
• 26 DeFronzo R A, Barzilai N, Simonson D C. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.  J Clin Endocrinol Metab. 1991;  73 1294-1301
• 27 Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich J E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.  N Eng J Med. 1995;  333 550-554
• 28 Maturana M A, Spritzer P M. Association between hyperinsulinemia and endogenous androgen levels in peri and postmenopausal women.  Metabolism. 2002;  51 238-243
• 29 Haffner S M, Newcomb P A, Marcus P M. Relation of sex hormones and dehydroepiandrosterona sulfate (DHEA-SO4) to cardiovascular risk factor in postmenopausal women.  Am J Epidemiol. 1995;  142 925-934
• 30 Bruun J M, Pedersen S B, Richelsen B. Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin.  Horm Metab Res. 2000;  32 537-541
• 31 Morin-Papunen L C, Koivunen R M, Ruokonen A, Martikainen H K. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.  Fertil Steril. 1998;  69 691-696
• 32 Nestler J E, Jakubowicz D J, Evans W S, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.  N Engl J Med. 1998;  338 1876-1880
• 33 de Leo V, La M arca, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome.  Fertil Steril. 1999;  72 282-285